Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
2010 · Molecular Cancer · 298 citations
https://doi.org/10.1186/1476-4598-9-188
X
Xue‐Ning Yang
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
283
Papers
6.6K
Citations
36
h-index
75
i10-index
Xue‐Ning Yang is an academic researcher from Ningbo University. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Lung Cancer Diagnosis and Treatment & Lung Cancer Research Studies. The author has an h-index of 36, co-authored 241 publications.
ORCID: 0000-0002-8346-2117Papers by this author
worksA phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
2017 · British Journal of Cancer · 172 citations
https://doi.org/10.1038/bjc.2016.456
Toward an Expert Level of Lung Cancer Detection and Classification Using a Deep Convolutional Neural Network
2019 · The Oncologist · 161 citations
https://doi.org/10.1634/theoncologist.2018-0908
Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study
2021 · JTO Clinical and Research Reports · 34 citations
https://doi.org/10.1016/j.jtocrr.2021.100257
Recent nanotechnology improvements in Curcumin bioavailability and related applications
2024 · Food Bioscience · 19 citations
https://doi.org/10.1016/j.fbio.2024.104660
Lipid-associated macrophages for osimertinib resistance and leptomeningeal metastases in NSCLC
2024 · Cell Reports · 19 citations
https://doi.org/10.1016/j.celrep.2024.114613
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat